Antibodies against complement system in SLE and their potential diagnostic utility

Current Rheumatology Reviews

Volumn 5, Issue 1, 2009, Pages 58-63

  Horák, Pavel ^a   Zadražil, Josef ^a   Ciferská, Hana ^a   Heřmanová, Zuzana ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Anti Clq antibodies; Antibodies; Complement system; Serological marker; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; NEPHRITIC FACTOR;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIAGNOSTIC VALUE; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIPODYSTROPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 65949115312     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339709787315384     Document Type: Review

References (71)

1. Sherer Y, Gorstein A, Fritzler M, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Sem Arthritis Rheum 2004; 34: 501-7.
2. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4(Suppl 3): 279-93.
3. Pickering MC, Walport MJ. The complement system. In: Hochberg MC, Silman AJ, Smolen Ed, Rheumatology, Third Edition, Mosby 2003; 1323-36.
4. Walport MJ. Complement. Second of Two Parts. N Engl J Med 2001; 344: 1140-44.
5. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199: 265-85.
6. Herrmann M, Voll RE, Lolowos W, et al. Etiopathogenesis of systemic lupus erythematosus. Immunologist 2000; 8: 345-50.
7. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiol 2002; 205: 395-406.
8. Pickering MC, Botto M, Taylor PR, Lachman PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-34.
9. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525-28.
10. Prodeus AP, Gorg S, Shen LM, et al. A critical role of complement in maintenance of self tolerance. Immunity 1998; 9: 721-31.
11. Paul E, Carrol MC. SAP less chromatin triggers systemic lupus erythematosus. Nat Med 1999; 5: 607-8.
12. Gommerman JL, Carrol MC. Negative selection of B lymphocytes: a novel role for innate immunity. Immunol Rev 2000; 173: 120-30.
13. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacol 1999; 42: 47-52.
14. Law SK, Lichtenberg NA, Holcombe FH, Levin RP. Interaction between the labile binding sites of the fourth and fifth human complement proteins and erythrocyte cell membranes. J Immunol 1980; 125: 634-39.
15. Barilla-LaBarca ML, Atkinson JP. Rheumatic syndromes associated with complement deficiency. Curr Opin Rheumatol 2003; 15: 55-60.
16. Mitchell DA, Pickering MC, Warren J, et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002; 168: 2538-43
17. Hauptmann G, Grosshans E, Heid E. Systemic lupus erythematosus and hereditary complement deficiency: A case with total C4 defect. Ann Dermatol Syphil Paris 1974; 101: 479-96.
18. Hannema AJ, Kluin-Nelemans JC, Hack CE, Eerenbergerbelmer AJM, Mallee C, Vanhelden HPT. SLE like syndrome and functional deficiency of C1q in members of a large family. Clin Exp Immunol 1984; 55: 106-14.
19. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport M. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324.
20. Hauptmann G, Grosshan E, Heid E, Mayer S, Basset A. Lupus erythemateux aigu avec deficit complet de la fraction C4 du complement. Nouv Press Med 1974; 3: 881-82.
21. Schur PH. Inherited complement component abnormalities. Annu Rev Med 1986; 37: 333-46.
22. Ratnoff WD. Inherited deficiencies of complement in rheumatic diseases. Rheum Dis Clin N Am 1996; 22: 75-94.
23. Glass D, Raum D, Gibson D, Stillman JS, Schur PH. Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest 1976; 58: 853-61.
24. Hauptmann G, Tappeiner G, Schifferli JA. Inherited deficiency of the fourth component of human complement. Immunodef Rev 1988; 1: 3-22.
25. Fielder AH, Walport MJ, Batchelor JR, et al. Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. BMJ 1983; 286: 425-28.
26. Christiansen FT, Dawkins RL, Uko G, McCluskey J, Kay PH, Zilko PJ. Complement allotyping in SLE: association with C4A null. Aust NZ J Med 1983; 13: 483-88.
27. Stone NM, Williams A, Wilkinson JD, Bird G. Systemic lupus erythematosus with C1q deficiency. Brit J Dermatol 2000; 142: 521-24.
28. Berkel AI, Petry F, Sanal O, et al. Development of systemic lupus erythematosus in a patient with selective complement C1q deficiency. Eur J Ped 1997; 156: 113-15.
29. Botto M, Walport MJ. Hereditary deficiency of C3 in animals and humans. Int Rev Immunol 1993; 10: 37-50.
30. Trouw LA, Roos A, Daha MR. Autoantibodies to complement components. Mol Immunol 2001; 38:199-206.
31. Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12: 619-24.
32. Agnello V, Koffler D, Eisenberg JW, Winchester RJ, Kundel HG. C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 1971; 134: 228-41.
33. Trouw LA, Groenevelt TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-88.
34. Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 2005; 5: 243-51.
35. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 2005; 27: 276-85.
36. Antes U, Heinz HP, Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 457-64.
37. Uwatoko S, Aotsuka S, Okawa M, et al. C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 69: 98-106.
38. Uwatoko S, Mannik M. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J Clin Invest 1988; 82: 816-24.
39. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Molecular Immunology 2007; 44: 2147-51.
40. Holers VM. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 2004; 114: 616-19.
41. Flierman R, Daha R. Pathogenic role of anti C1q autoantibodies in the development of lupus nephritis - a hypotesis. Mol Immunol 2007; 44: 133-38.
42. Siegert CE, Daha MR. C1q as antigen in humoral autoimmune responses. Immunobiology 1998; 199: 295-302.
43. Horvath L, Czirjak L, Fekete B, et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19: 667-72.
44. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Kamashta MA. Anti-C1q antibodies in nephritis: correlation between titers and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-48.
45. Moroni G, Trendelenburg M, Del Papa N, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-98.
46. Coremans IE, Spronk PE, Bootsma H, et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 595-601.
47. Coremans IE, Daha MR, van der Voort EA, Siegert CE, Breedveld FC. Subclass distribution of IgA and IgG antibodies against Clq in patients with rheumatic diseases. Scand J Immunol 1995; 41: 391-7.
48. Wisnieski JJ, Naff GB. Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum 1989; 32: 1119-27.
49. Trendelenburg M, Schifferli JA. Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus. J Rheumatol 2000; 59: 172-75.
50. Siegert CE, Daha MR, Halma C, van der Voort EA, Breedveld FC. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol 1992; 10: 19-23.
51. Siegert CE, Daha MR, Swaak AJ van der Voort EA, Breedveld FC. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1993; 67: 204-209.
52. Saadoun D, Sadallah S, Trendelenburg M, et al. Anti-1q antibodies in hepatitis C virus infection. Clin Exp Immunol 2006; 145: 308-12.
53. Lienesch DW, Sherman KE, Metzger A, Shen GQ. Anti-C1q antibodies in patients with chronic hepatitis C infection. Clin Exp Rheumatol 2006; 24: 183-85.
54. Fremeaux-Bacchi V, Noel LH, Schifferli JA. No lupus nephritis in the absence of anti-C1q autoantibodies? Nephrol Dial Transplant 2002; 17: 2041-43.
55. Kumar A, Gupta R, Varghese T, Pande RM, Singal VK, Garg OP. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian J Med Res 1999; 10: 190-3.
56. Monova D, Monov S, Rosenova K, Argirova T. Autoantibodies against C1q: view on association between systemic lupus erythematosus disease manifestation and C1q autoantibodies. Ann Rheum Dis 2002; 61: 563-64.
57. Trendelenburg M, Marfurt J, Gerber SA, Tyndal A, Shifferli JA. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody negative patients. Arthritis Rheum 1999; 42: 187-88.
58. Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al. High prevalence of anti C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115-21.
59. Mosca M, Chimenti D, Pratesi F, et al. Prevalence and clinico-serological correlations of anti enolase, anti C1q, and dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 695-97.
60. Jaekell HP, Trabandt A, Grobe N, Werle E. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus 2006; 15: 335-45.
61. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with Rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74.
62. Horák P, Heřmanová Z, Zadražil J, et al. C1q complement component and antibodies reflect SLE activity and kidney involvement. Clin Rheumatol 2006; 25: 532-36.
63. Kazatchkine MD, Fearon DT. Deficiencies of human complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodef Rev 1990; 2: 17-41.
64. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR) deficiency in erythrocytes from the patients with systemic lupus erythematosus. J Exp Med 1981; 155: 1427-38.
65. Tausk FA, McCutchan A, Spechko P, Schreiber RD, Gigli I. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 1986; 78: 977-82.
66. Kanto T, Hayashi N, Takehara T, et al. Low expression of erythrocyte complement receptor type 1 in chronic hepatitis C patients. J Med Virol 1996; 50: 126-34.
67. Sadallah S, Hess C, Trendelenburg M, Vedeler C, Lopez-Trasca M, Schifferli JA. Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients Clin Exp Immunol 2003; 131: 174-81.
68. Davies KA, Hird V, Stewart S, et al. A study of in vivo immune complex formation and clearance in man. J Immunol 1990; 144: 4613-20.
69. Cooper NR. The classical complement pathway: activation and regulation of first complement component. Adv Immunol 1985; 37: 151-216.
70. Levy Y, George J, Yona E, Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998; 18: 55-60.
71. D'Incan M, Tridon A, Ponard D, et al. Acquired angioedema with C1 inhibitor deficiency: Is the distinction between type I and type II still relevant? Dermatology 1999; 199: 227-30.